Clinical implications of the serum CA19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancer-Reference-Cited by-同舟云学术

Clinical implications of the serum CA19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancer

Published:2020-07 Issue:5 Volume:20 Page:919-928
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Takahashi Hidenori^ORCID,Yamada Daisaku,Asukai Kei,Wada Hiroshi,Hasegawa Shinichiro,Hara Hisashi^ORCID,Shinno Naoki,Ushigome Hajime,Haraguchi Naotsugu,Sugimura Keijiro,Yamamoto Kazuyoshi^ORCID,Nishimura Junichi,Yasui Masayoshi,Omori Takeshi^ORCID,Miyata Hiroshi,Ohue Masayuki,Yano Masahiko^ORCID,Sakon Masato,Ishikawa Osamu

Funder

Osaka Foundation for The Prevention of Cancer and Life-style related Diseases

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference44 articles.

1. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies;Le Large Tys;Semin Canc Biol,2017

2. Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS);Bockhorn;Surgery,2014

3. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017;Isaji;Pancreatology : Off J Int Assoc Pancreatol (IAP),2018

4. Ca19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy;Hartwig;Ann Surg Oncol,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma;Annals of Surgical Oncology;2024-06-26

2. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis;Annals of Surgical Oncology;2024-02-22

3. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: A retrospective cohort study;International Journal of Surgery;2024-02-19

4. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers;Annals of Surgical Oncology;2024-02-17

5. Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer;Annals of Hepato-Biliary-Pancreatic Surgery;2024-02-01